Z Squared Inc. (NASDAQ: ZSQR)

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company focused on acquiring, developing, and advancing cell therapy technologies for cancer and other diseases. The company’s primary business model centers on progressing its current product portfolio through internal development and strategic partnerships with entities possessing novel therapies or drug delivery technologies. It actively pursues in-license, out-license, co-development, and other collaborative arrangements in therapeutic areas such as oncology and autoimmune disease.

Revenue generation is not currently occurring as the company remains in the pre-revenue stage of development. Its activities are centered on research and development, licensing agreements, and advancing product candidates toward clinical and commercial stages. The company does not sell products or services and has no reported revenue from operations.

The company operates through the following segments: Coeptis Therapeutics Inc., SNAP Biosciences Inc., GEAR Therapeutics Inc., Coeptis Pharmaceuticals Inc., and Coeptis Pharmaceuticals LLC.

• Coeptis Therapeutics Inc. serves as the primary operating subsidiary and oversees core development efforts including the CD38-GEAR-NK and CD38-Diagnostic programs in collaboration with Vy-Gen Bio Inc., as well as the SNAP-CAR platform licensed from the University of Pittsburgh.

• SNAP Biosciences Inc. is a majority-owned subsidiary involved in supporting research and development activities related to the SNAP-CAR platform, including preclinical studies and intellectual property management.

• GEAR Therapeutics Inc. is a majority-owned subsidiary focused on advancing the GEAR technology platform, which enables modified natural killer cells to be co-administered with targeted monoclonal antibodies without being neutralized.

• Coeptis Pharmaceuticals Inc. is a wholly owned subsidiary that holds certain intellectual property and supports development activities tied to the company’s pipeline assets, including those related to the Vy-Gen collaborations.

• Coeptis Pharmaceuticals LLC is a wholly owned limited liability company that functions as a holding entity for specific assets and rights associated with the company’s therapeutic programs and partnerships.

Coeptis Therapeutics Holdings, Inc. operates in the highly competitive cell therapy and immunotherapy sector, where it faces competition from established biotechnology firms developing CAR-T, NK cell, and other immune-based treatments. The company differentiates itself through its SNAP-CAR platform’s use of antibody adaptors and covalent bonding to potentially reduce toxicity and relapse in solid tumor applications, as well as its GEAR technology designed to protect CD38-positive natural killer cells from destruction by anti-CD38 monoclonal antibodies.

The company serves patients with cancer and other diseases, particularly those with hematologic malignancies such as acute myeloid leukemia, multiple myeloma, and chronic lymphocytic leukemia, as well as individuals suffering from viral infections and solid tumors. Its diagnostic tool, CD38-Diagnostic, is intended for use by healthcare providers to identify patients likely to benefit from anti-CD38 monoclonal antibody therapies.